Parexel International is enhancing its early-phase cardiac safety capabilities through a new alliance with Mortara Instrument, a worldwide manufacturer and distributor of ECG devices and related technology based in Milwaukee, WI. Specifically, Parexel will supplement its ECG equipment with Mortara Instrument's Surveyor Telemetry Central System, which is already in use at the company's Baltimore, MD, early phase clinical unit.
"This relationship represents our commitment to providing comprehensive early phase cardiovascular expertise and capabilities, such as intensive ECG and thorough QT/QTc studies, supported by enabling technologies,” said Michelle Middle, Parexel's corporate VP and worldwide head of early phase, in a company press release.
Mortara's high-tech solution will automate the process of acquiring and recording ECGs for Parexel, which are wirelessly transmitted from devices worn by clinical trial participants.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access